Article
Endocrinology & Metabolism
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Summary: In Korea, the combination of SGLT2i and GLP-1RA has been shown to significantly lower blood sugar levels in patients with type 2 diabetes, with good tolerability and safety.
DIABETES & METABOLISM JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Carolyn S. P. Lam, Chinthanie Ramasundarahettige, Kelley R. H. Branch, Naveed Sattar, Julio Rosenstock, Richard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth Niemoeller, Nardev S. Khurmi, Seungjae Baek, Hertzel C. Gerstein
Summary: The analysis of the AMPLITUDE-O trial suggests that the efficacy and safety of Efpeglenatide are not impacted by concurrent use of SGLT2 inhibitors. These data support the combined use of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
Article
Cardiac & Cardiovascular Systems
Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzen, Ann-Marie Svensson, Bjoern Eliasson
Summary: This observational study indicated that treatment with GLP-1RA and SGLT-2i result in very similar cardiorenal outcomes. In the short term, treatment with GLP-1RA seem to be associated with lower risks of stroke and peripheral artery disease, whereas SGLT-2i seem to be nominally associated with lower risk of heart failure and total mortality.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno
Summary: The study indicates that adding SGLT2 inhibitors to GLP-1 receptor agonist therapy in patients with type 2 diabetes can provide additional cardiovascular benefits, especially in reducing cardiovascular endpoint events and heart failure hospitalizations.
Article
Endocrinology & Metabolism
Hui Chen, Xiongze Zhang, Nanying Liao, Yuying Ji, Lan Mi, Yuhong Gan, Yongyue Su, Feng Wen
Summary: This study investigated the expression of GLP-1R, SGLT1, SGLT2, GLUT1, and GLUT2 in DR patients and found that GLP-1R and SGLT2 were significantly decreased in PDR patients. Their decrease was associated with an increased level of expression of TNF-alpha and IFN-gamma, suggesting a potential correlation between defective GLP-1R and SGLT2 signaling and immune response cytokines in PDR patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
Summary: Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors has superior effects on reducing HbA1c, body weight, fasting plasma glucose (FPG), 2 h postprandial glucose (2 h PG), systolic blood pressure (SBP), body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus compared to monotherapy. However, the efficacy of these effects gradually decreases over time and there is an increased risk of hypoglycemia and certain adverse events associated with combination therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Nutrition & Dietetics
Kai Aoki, Takuji Suzuki, Fang Hui, Takuro Nakano, Koki Yanazawa, Masato Yonamine, Shinichiro Fujita, Takehito Sugasawa, Yasuko Yoshida, Naomi Omi, Yasushi Kawakami, Kazuhiro Takekoshi
Summary: This study showed that acute low-intensity exercise affects the expression of molecules involved in intestinal carbohydrate digestion and absorption through GLP-2, leading to higher plasma GLP-2 levels and increased expression of GLP-2 receptor, SI, and GLUT2 in the jejunum in mice. These results suggest that exercise may be beneficial for small intestine function in individuals with intestinal frailty.
Article
Biochemistry & Molecular Biology
Teodor Salmen, Ali Abbas Rizvi, Manfredi Rizzo, Valeria-Anca Pietrosel, Ioana-Cristina Bica, Cosmina Theodora Diaconu, Claudia Gabriela Potcovaru, Bianca-Margareta Salmen, Oana Andreia Coman, Anca Bobirca, Roxana-Adriana Stoica, Anca Stoian
Summary: In this retrospective study, both SGLT-2i and GLP-1 RAs showed efficacy in weight control, metabolic control, and diastolic blood pressure control when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications in a real-life setting.
Article
Cardiac & Cardiovascular Systems
Yeong-Min Lee, Soon-Hee Lee, Tae-Hee Kim, Eun-Ji Park, Young-Ah Park, Jae-Sik Jang
Summary: This study found that both GLP-1 agonists and SGLT-2 inhibitors have comparable cardiovascular outcomes in patients with type 2 diabetes. However, SGLT-2 inhibitors are associated with a more pronounced reduction in hospitalization for heart failure and a lower risk of treatment discontinuation compared to GLP-1 agonists.
CARDIOLOGY JOURNAL
(2022)
Article
Endocrinology & Metabolism
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Summary: This study compared the risk of diabetic retinopathy (DR) between patients using sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care. The results showed that patients receiving SGLT2is had a lower risk of proliferative DR and vitreoretinal interventions compared to those using GLP1-RAs, although the rate of any DR was comparable between the two groups.
DIABETES & METABOLISM JOURNAL
(2023)
Article
Medicine, General & Internal
Daria M. Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kaluzna-Oleksy, Maciej Lesiak, Ewa Straburzynska-Migaj
Summary: SGLT2 inhibitors not only show excellent performance in improving glycemic control, but also have a positive impact on cardiovascular and renal outcomes. New guidelines recommend SGLT2 inhibitors as first-line treatment for heart failure patients, bringing new hope for the treatment of heart failure patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Oliver Kuss, Marie Elisabeth Opitz, Lea Verena Brandstetter, Sabrina Schlesinger, Michael Roden, Annika Hoyer
Summary: Treatment heterogeneity and identification of clinical predictors are prerequisites for the application of precision medicine. This study utilized meta-regression analysis on placebo-controlled randomized trials of type 2 diabetes treatment and found that there is an increase in the variability of glycaemic control after treatment, with GLP-1 receptor agonists showing the most pronounced effect.
Article
Endocrinology & Metabolism
Rainer U. Pliquett, Linda Golle, Andreas Wienke, Matthias Girndt
Summary: Real-world data suggest that incretin mimetic therapy is not widely used in type-2 diabetics with atherosclerotic vascular disease. A study on type-2 diabetics undergoing myocardial revascularization found that incretin mimetics were associated with lower prevalence, while hypoglycemic events were more frequent in insulin-treated patients.
Article
Primary Health Care
Hanifah Davis, Rachel Heilmann, Jessica Milchak, Thomas Delate
Summary: The study found that characteristics associated with A1C reduction with GLP-1 or SGLT-2 use include medication persistence, congestive heart failure comorbidity, phentermine dispensing, care management team (CMT) enrollee, and higher baseline A1C levels.
Article
Health Care Sciences & Services
Abhipree Sharma, Stephen Wood, J. Simon Bell, Miles J. De Blasio, Jenni Ilomaki, Rebecca H. Ritchie
Summary: SGLT2i demonstrated favorable effects in reducing major adverse cardiovascular events (MACE) in men with type 2 diabetes (T2D) compared to GLP-1RAs, but not in women. However, analogous benefits were observed in men aged 65 years and above, men with baseline heart failure, and women with atherosclerotic cardiovascular disease (ASCVD).
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Review
Urology & Nephrology
Benjamin Talbot, Alan Cass, Robert Walker, Lai Hooi, Meg Jardine, Min Jun, Kris Rogers, Louisa Sukkar, Brendan Smyth, Martin Gallagher
Summary: This study examined whether there were differences in survival and causes of death among participants from Australia, Malaysia, and New Zealand in the extended follow-up of the SHARP study. It was found that participants from Malaysia and New Zealand had a higher risk of death compared to participants from Australia.
Article
Transplantation
Denise M. J. Veltkamp, Yiman Wang, Yvette Meuleman, Friedo W. Dekker, Wieneke M. Michels, Paul J. M. van der Boog, Aiko P. J. de Vries
Summary: This study investigated the relationship between symptom prevalence and burden with health-related quality of life (HRQOL) in kidney transplant recipients (KTRs). The results showed that female KTRs reported more symptoms and younger KTRs experienced more symptoms related to depression and changes in physical appearance.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Transplantation
Robin Lengton, Esmee M. van der Willik, Esther N. M. de Rooij, Yvette Meuleman, Saskia Le Cessie, Wieneke M. Michels, Marc Hemmelder, Friedo W. Dekker, Ellen K. Hoogeveen
Summary: This study investigated the association between residual estimated glomerular filtration rate (eGFR), dialysis adequacy, or serum phosphate level and chronic kidney disease-associated pruritus (CKD-aP) in incident dialysis patients. The results showed that higher residual eGFR and lower serum phosphate level, but not the dialysis dose, were related to a lower burden of CKD-aP in dialysis patients.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Yang Xu, Shujie Dong, Edouard L. Fu, Arvid Sjolander, Morgan E. Grams, Elizabeth Selvin, Juan Jesus Carrero
Summary: Higher long-term visit-to-visit HbA1c variability is consistently associated with the risks of CKD progression, AKI, and worsening of albuminuria.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Article
Urology & Nephrology
Juan-Jesus Carrero, Edouard L. Fu, Yingying Sang, Shoshana Ballew, Marie Evans, Carl-Gustaf Elinder, Peter Barany, Lesley A. Inker, Andrew S. Levey, Josef Coresh, Morgan E. Grams
Summary: Routine cystatin C testing provides real-world evidence about the differences between estimated glomerular filtration rate based on cystatin C and creatinine, and their association with various clinical outcomes. This observational study in Sweden found that patients with lower eGFR(cys) than eGFR(cr) had a higher risk of kidney failure, acute kidney injury, atherosclerotic cardiovascular disease, heart failure, and death.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Letter
Anesthesiology
Thomas Payne, Mark Coburn, Stefan Dieleman, Gillian Heller, Meg Jardine, Yahya Shehabi, Robert D. Sanders
BRITISH JOURNAL OF ANAESTHESIA
(2023)
Article
Urology & Nephrology
Edouard L. L. Fu, Elvira D'Andrea, Deborah J. Wexler, Elisabetta Patorno, Julie M. Paik
Summary: In US patients with CKD and type 2 diabetes receiving routine care, the use of SGLT2i was associated with higher risks of genital infections and potentially lower limb amputations and nonvertebral fractures.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Urology & Nephrology
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, Brendon L. L. Neuen, Jasper Stevens, Vlado Perkovic, Adeera Levin, Kenneth W. W. Mahaffey, Carol Pollock, Tom Greene, David C. C. Wheeler, Meg J. J. Jardine, Hiddo J. L. Heerspink
Summary: In the CREDENCE trial, canagliflozin was found to have a greater impact on eGFR slope in patients with higher baseline HbA1c levels, indicating that patients with poorer glycemic control may benefit more from the drug.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Endocrinology & Metabolism
Amy Kang, Brendan Smyth, Brendon L. L. Neuen, Hiddo J. L. Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George Bakris, David M. M. Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C. C. Wheeler, Kenneth W. W. Mahaffey, Vlado Perkovic, Meg J. J. Jardine
Summary: The aim of this study was to assess the risk of non-genital skin and soft tissue infections (SSTIs) associated with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. A post hoc analysis of two trials was conducted, and the results showed that canagliflozin did not significantly affect the risk of non-genital SSTIs or non-genital fungal SSTIs compared with placebo. This suggests that the changes in skin microenvironment mediated by SGLT2 inhibitors may not have meaningful clinical consequences.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Edouard L. Fu, Elisabetta Patorno, Brendan M. Everett, Muthiah Vaduganathan, Scott D. Solomon, Raisa Levin, Sebastian Schneeweiss, Rishi J. Desai
Summary: This study aimed to evaluate the comparative effectiveness of SGLT2i vs. sitagliptin in older adults with HF and type 2 diabetes and found that initiating SGLT2i was associated with a lower risk of the primary composite outcome compared to sitagliptin.
EUROPEAN HEART JOURNAL
(2023)
Review
Urology & Nephrology
Edouard L. Fu
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Urology & Nephrology
Edouard L. Fu, Andrew S. Levey, Josef Coresh, Carl-Gustaf Elinder, Joris I. Rotmans, Friedo W. Dekker, Julie M. Paik, Peter Barany, Morgan E. Grams, Lesley A. Inker, Juan-Jesus Carrero
Summary: Cystatin C is recommended as a confirmatory test to eGFR when more precise estimates are needed for clinical decision making. However, it is uncertain whether eGFR(cr-cys) is the most accurate estimate in real-world settings, especially when there are large discordances between eGFR(cr) and eGFR(cys).
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Multidisciplinary Sciences
Mikko Haapio, Merel van Diepen, Retha Steenkamp, Jaakko Helve, Friedo W. Dekker, Fergus Caskey, Patrik Finne
Summary: Mortality prediction is crucial in long-term kidney replacement therapy (KRT) for treatment decisions and resource planning. Existing models have mostly been internally validated, but this study externally validated the performance of two previously constructed models in the Dutch and UK KRT populations. The models showed good performance and encourage widespread implementation in European KRT populations.
Article
Health Care Sciences & Services
Liselotte F. S. Langenhuijsen, Roemer J. Janse, Esmee Venema, David M. Kent, Merel van Diepen, Friedo W. Dekker, Ewout W. Steyerberg, Ype de Jong
Summary: Using the PROBAST, researchers explored the trends of risk of bias in prediction research and assessed the inter-rater agreement. They found that high bias was prevalent in the Analysis domain and the overall bias trends remained relatively stable over time. The inter-rater agreement was low and could potentially be improved by altering the PROBAST or providing training.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Urology & Nephrology
Willemijn A. L. Vrijlandt, Margriet F. C. de Jong, Jelmer R. Prins, Kate Bramham, Patrick J. W. S. Vrijlandt, Roemer J. Janse, Faizan Mazhar, Juan Jesus Carrero
Summary: This study aimed to evaluate the burden of chronic kidney disease (CKD) and associated birth rates in an entire region. Through a retrospective cohort study of women of childbearing age in Stockholm, researchers found that 0.50% of individuals had probable CKD, and women with probable CKD had a lower birth rate compared to those without CKD.
JOURNAL OF NEPHROLOGY
(2023)